Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical pharmacology and therapy

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/clpt.2012.66PMID 22739144PMCID PMC3785311
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record

  2012cited by this paper
• Pharmacogenomics at the Tipping Point: Challenges and Opportunities

  2011cited by this paper
• Detecting Drug Interactions From Adverse‐Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels

  2011cited by this paper
• Weighing the benefits of high-dose simvastatin against the risk of myopathy.

  2011cited by this paper
• Patient-centric clinical pharmacology advances the path to personalized medicine.

  2011cited by this paper
• Electronic Medical Records for Genetic Research: Results of the eMERGE Consortium

  2011cited by this paper
• DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA.

  2010cited by this paper
• Hospitalization costs associated with warfarin‐related bleeding events among older community‐dwelling adults

  2010cited by this paper
• Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?

  2010cited by this paper
• Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records

  2010cited by this paper
• Prasugrel vs. clopidogrel for cytochrome P450 2C19‐genotyped subgroups: integration of the TRITON‐TIMI 38 trial data

  2010cited by this paper
• A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing

  2010cited by this paper
• Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.

  2010cited by this paper
• Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

  2010cited by this paper
• The path to personalized medicine.

  2010cited by this paper
• Application of information technology: MedEx: a medication information extraction system for clinical narratives

  2010cited by this paper
• Estimation of the warfarin dose with clinical and pharmacogenetic data.

  2009cited by this paper
• Opportunities and challenges for the NIH--an interview with Francis Collins. Interview by Robert Steinbrook.

  2009cited by this paper
• A Meta-Analysis

  2009cited by this paper
• Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation

  2009cited by this paper
• Opportunities and Challenges for the NIH — An Interview with Francis Collins

  2009cited by this paper
• Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

  2009cited by this paper
• Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use

  2008cited by this paper
• HLA-B*5701 screening for hypersensitivity to abacavir.

  2008cited by this paper
• HLA-B*5701 screening for hypersensitivity to abacavir.

  2008cited by this paper
• The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV

  2008cited by this paper
• Multi-mutational analysis of fifteen common mutations of the glucose 6-phosphate dehydrogenase gene in the Mediterrranean population.

  2008cited by this paper
• Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine

  2008cited by this paper
• SLCO1B1 variants and statin-induced myopathy--a genomewide study.

  2008cited by this paper
• Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank.

  2007cited by this paper
• Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel.

  2006cited by this paper
• Pharmacogenetics and pharmacogenomics: development, science, and translation.

  2006cited by this paper
• CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis

  2005cited by this paper
• Challenges and opportunities.

  1996cited by this paper
• Nature of hemolytic crises and the fate of G6PD deficient, drug-damaged erythrocytes in Sardinians.

  1967cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People

  2025cites this paper
• Pharmacogenomics-Based Detection of Variants Involved in Pain, Anti-inflammatory and Immunomodulating Agents Pathways by Whole Exome Sequencing and Deep in Silico Investigations Revealed Novel Chemical Carcinogenesis and Cancer Risks

  2025cites this paper
• Nationwide Implementation of Essential Pharmacogenomic Testing in the Netherlands: A Decision-Analytic Model of Lives Saved and Cost-Effectiveness

  2025cites this paper
• Real‐World Utilization of Medications With Pharmacogenetic Recommendations in Older Adults: A Scoping Review

  2025cites this paper
• A feasibility study on implementing pre-emptive pharmacogenomics testing in outpatient clinics in Singapore (IMPT study)

  2025cites this paper
• Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test

  2025cites this paper
• Implementation of HLA-related genotype-guided prescribing in Singapore.

  2024cites this paper
• Estimated clinical utility of multi-gene pharmacogenetic testing in a retrospective cohort of gynecology patients.

  2024cites this paper
• A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care

  2024cites this paper
• Estimation of the benefit from pre‐emptive genotyping based on the nationwide cohort data in South Korea

  2024cites this paper
• Implementation of Pre-emptive Pharmacogenomics Testing in Outpatient Clinics in Asia (IMPT study)

  2024cites this paper
• Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical Implementation.

  2024cites this paper
• Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population

  2024cites this paper
• Implementing preemptive, multigene, pharmacogenomic testing in the inpatient setting: Preliminary results from a small, rural facility

  2023cites this paper
• Pharmacogenomic and Statistical Analysis.

  2023cites this paper
• Use of a multi-gene pharmacogenetic panel reduces adverse drug effects

  2023cites this paper
• Pharmacogenomics in practice: a review and implementation guide

  2023cites this paper
• Implementation of pharmacogenetic testing in medication reviews in a hospital setting

  2023cites this paper
• Patient-Level Exposure to Actionable Pharmacogenomic Medications in a Nationally Representative Insurance Claims Database

  2023cites this paper
• Effectiveness of pharmacogenomics on the response and remission of treatment-resistant depression: a meta-analysis of randomised controlled trials

  2023cites this paper
• Most patients with disorders of gut‐brain interaction receive pharmacotherapy with major or moderate drug‐gene interactions

  2023cites this paper
• Validation of Pharmacogenomic Interaction Probability (PIP) Scores in Predicting Drug–Gene, Drug–Drug–Gene, and Drug–Gene–Gene Interaction Risks in a Large Patient Population

  2022cites this paper
• Contraceptive exposure associates with urinary tract infection risk in a cohort of reproductive-age women: a case control study

  2022cites this paper
• Genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants.

  2022cites this paper
• Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.

  2022cites this paper
• From pharmacogenetics to pharmaco-omics: Milestones and future directions

  2022cites this paper
• Systemic Lupus Erythematosus Delivery Outcomes Are Unchanged Across Three Decades

  2022cites this paper
• Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population

  2022cites this paper
• Assessment of a Manual Method versus an Automated, Probability-Based Algorithm to Identify Patients at High Risk for Pharmacogenomic Adverse Drug Outcomes in a University-Based Health Insurance Program

  2022cites this paper
• Genetics professionals are key to the integration of genetic testing within the practice of frontline clinicians.

  2022cites this paper
• Role of Pharmacogenomics in Comprehensive Medication Management: Considerations for Employers

  2022cites this paper
• Identification, conservation, and expression of tiered pharmacogenes in zebrafish

  2022cites this paper
• Forecasting the future clinical events of a patient through contrastive learning

  2022cites this paper
• Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model

  2022cites this paper
• Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.

  2022cites this paper
• Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database

  2022cites this paper
• Nine-gene pharmacogenomics profile service: The Mayo Clinic experience

  2021cites this paper
• Moving Pharmacogenetics Into Practice: It’s All About the Evidence!

  2021cites this paper
• Multi-site investigation of strategies for the clinical implementation of preemptive pharmacogenetic testing

  2021cites this paper
• A Randomized Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression.

  2021cites this paper
• Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease

  2021cites this paper
• Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting

  2021cites this paper
• Precision Medicine and Health Disparities

  2021cites this paper
• Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients

  2021cites this paper
• Potentially actionable pharmacogenetic variants and symptom control medications in oncology

  2021cites this paper
• Opportunity for Genotype‐Guided Prescribing Among Adult Patients in 11 US Health Systems

  2021cites this paper
• The effect of medication reconciliation on generating an accurate medication list in a pharmacogenomics practice

  2021cites this paper
• Membership inference attacks against synthetic health data

  2021cites this paper
• Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions

  2021cites this paper
• Computational Methods and Approaches in Pharmacogenomic Research

  2021cites this paper
• Evaluating the feasibility of performing pharmacogenetic guided‐medication therapy management in a retirement community: A prospective, single arm study

  2021influential citation
• Life-time Actionable Pharmacogenetic Drug Use: A Population-based Cohort Study in 86 040 Young People With and Without Mental Disorders in Denmark

  2021cites this paper
• Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites.

  2021cites this paper
• Pharmacogenomics in kidney transplant recipients and potential for integration into practice

  2020cites this paper
• Increased Incidence of Resistant Hypertension in Patients With Systemic Lupus Erythematosus: A Retrospective Cohort Study

  2020cites this paper
• Pharmacogenetic Testing: The Ethics of Implementing in Clinical Practice for Chronic Pain Patients

  2020cites this paper
• Evaluation of clinical impact of pharmacogenomics knowledge involved in CPIC guidelines on Chinese pediatric patients.

  2020cites this paper
• Prescription patterns of outpatients and the potential of multiplexed pharmacogenomic testing

  2020cites this paper
• PARC report: health outcomes and value of personalized medicine interventions: impact on patient care.

  2020cites this paper
• Assessment of primary care practitioners' attitudes and interest in pharmacogenomic testing.

  2020cites this paper
• A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?

  2020cites this paper
• Pharmacogenomics for Primary Care: An Overview

  2020cites this paper
• Pharmacogenomics: Prescribing based on genetic variation

  2020cites this paper
• Farmacogenômica e Doença Cardiovascular: Onde Estamos e Para Onde Vamos

  2020cites this paper
• Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics

  2019cites this paper
• Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline

  2019cites this paper
• Pharmacogenomic potential in advanced cancer patients

  2019cites this paper
• Population-scale genomics-Enabling precision public health.

  2019cites this paper
• Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre‐emptive pharmacogenomic testing

  2019cites this paper
• A Decision-Theoretic Approach to Panel-Based, Preemptive Genotyping

  2019cites this paper
• Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing

  2019cites this paper
• The Evolution of DNA Sequencing in Pharmacogenomics

  2019cites this paper
• Pharmacogenomics

  2019cites this paper
• Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good

  2019influential citation
• Use of Pharmacogenetic Drugs by the Dutch Population

  2019cites this paper
• Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users

  2019cites this paper
• Genomics and personalised medicine : diagnostics, deep phenotyping and pharmacogenomics in cohorts of rare disease patients

  2019cites this paper
• Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact

  2019influential citation
• Characterizing the pharmacogenome using molecular inversion probes for targeted next-generation sequencing.

  2019cites this paper
• An end to pharmacogenetic exceptionalism

  2019cites this paper
• A stepwise approach to implementing pharmacogenetic testing in the primary care setting.

  2019cites this paper
• Development of the Initial Surveys for the All of Us Research Program.

  2019influential citation
• Implications of Pharmacogenomics to the Management of IBS.

  2019cites this paper
• User considerations in assessing pharmacogenomic tests and their clinical support tools

  2018cites this paper
• Phenome‐Wide Association Studies Uncover a Novel Association of Increased Atrial Fibrillation in Male Patients With Systemic Lupus Erythematosus

  2018influential citation
• Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome

  2018cites this paper
• Pharmacogenetics in Cardiovascular Medicine.

  2018cites this paper
• Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients

  2018cites this paper
• Phenome-wide association study identifies marked increased in burden of comorbidities in African Americans with systemic lupus erythematosus

  2018cites this paper
• Medication Exposure Patterns in Primary Care Patients Prescribed Pharmacogenetically Actionable Opioids.

  2018cites this paper
• Enhancing diversity to reduce health information disparities and build an evidence base for genomic medicine.

  2018cites this paper
• Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults

  2018cites this paper
• The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice

  2018cites this paper
• The Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary care.

  2018cites this paper
• Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit

  2018cites this paper
• Learning from Longitudinal Data in Electronic Health Record and Genetic Data to Improve Cardiovascular Event Prediction

  2018cites this paper
• Learning from Longitudinal Data in Electronic Health Record and Genetic Data to Improve Cardiovascular Event Prediction

  2018cites this paper
• Clinical pharmacogenetics: how do we ensure a favorable future for patients?

  2018cites this paper
• Patient Care Situations Benefiting from Pharmacogenomic Testing

  2018cites this paper
• Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects

  2018cites this paper